Continuous antigenic stimulation system (CASS) as a new immunization strategy

Vaccine

Volumn 22, Issue 29-30, 2004, Pages 3902-3910

  Gomez Vargas, Andrew ^a   Rosenthal, Kenneth L ^a   McDermott, Mark R ^a   Hortelano, Gonzalo ^a,b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Antigen stimulation system; Immune response; Immunization strategy

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G2A ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; CELL ENCAPSULATION; CELL SECRETION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; IMPLANTATION; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE; TH1 CELL; TRANSGENE;

ANIMALS; ANTIBODY FORMATION; ANTIGENS; BIOLOGICAL AVAILABILITY; CELL LINE; CROSS REACTIONS; DELAYED-ACTION PREPARATIONS; FACTOR IX; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYOBLASTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 4444358396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.04.010     Document Type: Article

References (39)

1. Ada G. Progress towards achieving new vaccine and vaccination goals. Intern. Med. J. 33:2003;297-304
2. Mason K.M., Bigley N.J., Fink P.S. Development of a novel in vitro co-culture system for studying host response to native bacterial antigens. J. Immunol. Methods. 211:1998;147-158
3. Gregersen J.P. DNA vaccines. Naturwissenschaften. 88:2001;504-513
4. Downard K.M. Contributions of mass spectrometry to structural immunology. J. Mass Spectrom. 35:2000;493-503
5. Leong A.S., Lee E.S., Yin H., Kear M., Haffajee Z., Pepperall D. Superheating antigen retrieval. Appl. Immunohistochem. Mol. Morphol. 10:2002;263-268
6. Vlachaki M.T., et al. Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. Mol. Ther. 6:2002;342-348
7. Morral N., O'Neal W., Zhou H., Langston C., Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum. Gene Ther. 8:1997;1275-1286
8. Srivastava I.K., Liu M.A. Gene vaccines. Ann. Intern. Med. 138:2003;550-559
9. O'Hagan Derek T., Singh Manmohan, Gupta Rajesh K. Poly(lactide-co- glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 32(3):1998;225-246
10. Hortelano G., Al-Hendy A., Ofosu F.A., et al. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 87:1996;5095-5103
11. Hortelano G., Wang L., Xu N., et al. Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia. 7:2001;207-214
12. Tomokiyo K., Teshima K., Nakatomi Y., Watanabe T., Mizuguchi J., Nozaki C., et al. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B. Thromb. Res. 102:2001;363-374
13. Chang P.L., Van Raamsdonk J.M., Hortelano G., Barsoum S.C., MacDonald N.C., Stockley T.L. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotechnol. 17:1999;78-83
14. Gallichan W.S., Rosenthal K.L. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology. 224:1996;487-497
15. Lewkowich I.P., HayGlass K.T. Endogenous IFN-gamma and IL-18 production directly limit induction of type 2 immunity in vivo. Eur. J. Immunol. 32:2002;3536-3545
16. Gallichan W.S., Rosenthal K.L. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1998;1155-1161
17. Ghendon Y. The immune response to influenza vaccines. Acta Virol. 34:1990;295-304
18. Uenishi H., Iwanami N., Yamagishi H., Nakatani T., Kawasaki T., Tamamura H., et al. Induction of cross-reactivity in an endogenous viral peptide non-reactive to FBL-3 tumor-specific helper T-cell clones. Microbiol. Immunol. 42:1998;479-484
19. Cusi M.G., Bianchi S., Santini L., Donati D., Valassina M., Valensin P.E., et al. Peripheral neuropathy associated with anti-myelin basic protein antibodies in a woman vaccinated with rubella virus vaccine. J. Neurovirol. 5:1999;209-214
20. Greenwood R., Wang B., Midkiff K., White G.C. 2nd, Lin H.F., Frelinger J.A. Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice. J. Thromb. Haemost. 1:2003;95-102
21. Ye X., Loeb K.R., Stafford D.W., Thompson A.R., Miao C.H. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid. J. Thromb. Haemost. 1:2003;103-111
22. Esser M.T., Marchese R.D., Kirstead L.S., Tussey L.G., Wang F., Chirmule N., Washabaugh M.W. Memory T cells and vaccines. Vaccine. 21:2003;419-430
23. Sprent J., Tough D.F., Sun S. Factors controlling the turnover of T memory cells. Immunol. Rev. 156:1997;79-85
24. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 406:2000;793-798
25. Cleland J.L. Protein delivery from biodegradable microspheres. Pharm. Biotechnol. 10:1997;1-43
26. Rosas J.E., Pedraz J.L., Hernandez R.M., Gascon A.R., Igartua M., Guzman F., et al. Remarkably high antibody levels and protection against P., falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres. Vaccine. 20:2002;1707-1710
27. Kissel T., Koneberg R., Hilbert A.K., et al. Microencapsulation of antigens using biodegradable polyesters: facts and phantasies. Behring Inst Mitt. 98:1997;172-183
28. Vajdy M., O'Hagan D.T. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. 51:2001;127-141
29. Jabbal-Gill I., Lin W., Kistner O., Davis S.S., Illum L. Polymeric lamellar substrate particles for intranasal vaccination. Adv. Drug Deliv. Rev. 51:2001;97-111
30. Toellner K.M., Luther S.A., Sze D.M., Choy R.K., Taylor D.R., MacLennan I.C., et al. T helper 1 (Th1) and Th2 characteristics start to develop during T cell priming and are associated with an immediate ability to induce immunoglobulin class switching. J. Exp. Med. 187:1998;1193-1204
31. Fields P.A., Kowalczyk D.W., Arruda V.R., Armstrong E., McCleland M.L., Hagstrom J.N., et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1:2000;225-235
32. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:2002;251-262
33. Wilson J.N., Nokes D.J., Dimmock N.J. Analysis of the relationship between immunogenicityand immunity for viral subunit vaccines. J. Med. Virol. 64:2001;560-568
34. Sigal L.J., Crotty S., Andino R., et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 398:1999;77-80
35. Kyburz D., Aichele P., Speiser D.E., Hengartner H., Zinkernagel R.M., Pircher H. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23:1993;1956-1962
36. Costa M.H., Sant'Anna O.A., de Araujo P.S., Sato R.A., Quintilio W., Silva L.V., et al. Conformational stability and antibody response to the 18kDa heat-shock protein formulated into different vehicles. Appl. Biochem. Biotechnol. 73:1998;19-28
37. Sailaja G., HogenEsch H., North A., Hays J., Mittal S.K. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther. 9:2002;1722-1729
38. Springer M.L., Hortelano G., Bouley D.M., Wong J., Kraft P.E., Blau H.M. Induction of angiogenesis by implantation of encapsulated primary myoblast expressing vascular endothelial growth factor. J. Gene Med. 2:2000;279-288
39. Kulseng B., Skjak-Braek G., Ryan L., Andersson A., King A., Faxvaag A., et al. Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation. 67:1999;978-984